|1.||Keefe, Deborah L: 19 articles (12/2012 - 12/2006)|
|2.||Solomon, Scott D: 15 articles (10/2015 - 05/2008)|
|3.||Zhang, Jack: 14 articles (12/2012 - 07/2007)|
|4.||Maggioni, Aldo P: 11 articles (06/2015 - 05/2008)|
|5.||Baschiera, Fabio: 10 articles (12/2015 - 12/2010)|
|6.||Persson, Frederik: 10 articles (03/2015 - 06/2008)|
|7.||Parving, Hans-Henrik: 10 articles (03/2015 - 06/2008)|
|8.||Dole, William P: 10 articles (05/2012 - 01/2007)|
|9.||Brunel, Patrick: 9 articles (12/2015 - 05/2012)|
|10.||McMurray, John J V: 9 articles (10/2015 - 05/2008)|
|1.||Hypertension (High Blood Pressure)
05/01/2007 - "In conclusion, combination treatment with aliskiren is a highly effective and well-tolerated therapeutic option for obese patients with hypertension who fail to achieve blood pressure control with first-line thiazide diuretic treatment."
07/01/2012 - "Adding aliskiren to combined antihypertensive therapy leads to significant improvement of hypertension control and myocardial function assessed by global longitudinal strain."
01/01/2013 - "Aliskiren administration to resistant hypertensive patients was effective in reducing BP. The present findings suggest aliskiren may be useful as a fourth-line or fifth-line treatment added to other drugs in the treatment of resistant hypertension."
01/01/2012 - "Aliskiren was effective for BP control and reduced UACR while maintaining eGFR and heart function in elderly CKD patients with hypertension."
01/01/2007 - "Monotherapy with aliskiren 150-300mg once daily was effective in lowering blood pressure (BP) and providing 24-hour BP control; it was generally well tolerated when administered for up to 1 year to patients with mild to moderate hypertension. "
01/01/2012 - "In both cases, the addition of the RAAS inhibitor aliskiren markedly improved damage and fibrosis markers, and prevented functional modifications in the peritoneal transport, as measured by the peritoneal equilibrium test. "
03/01/2013 - "1) The cardiac Ang II levels were significantly reduced while the plasma Ang II levels were not significantly decreased in rats treated with low doses of aliskiren; 2) echocardographic studies showed a decrease of left ventricle diameter (LVD), left ventricle posterior wall thickness (LVPW), left ventricle end diastolic volume (LVEDV) and increased ejection fraction (EF); 3) aliskiren improved the impulse propagation, increased the cardiac refractoriness and reduced the incidence of triggered activity; 4) perivascular and interstitial fibrosis were greatly reduced, which explains the increase in conduction velocity. "
01/01/2010 - "All sub-pressor and hypotensive doses of aliskiren significantly attenuated cardiac fibrosis, macrophage infiltration and coronary remodelling, and improved vascular endothelial function in db/db mice. "
03/01/2011 - "Renal protective effects of aliskiren beyond its antihypertensive property in a mouse model of progressive fibrosis."
03/01/2011 - "This study investigates the antifibrotic nephroprotective effects of aliskiren in a nonhypertensive mouse model for progressive renal fibrosis. "
|3.||Diabetic Nephropathies (Diabetic Nephropathy)
03/01/2013 - "Aliskiren may be a useful therapeutic agent in the treatment of type 2 diabetes and diabetic nephropathy."
01/01/2012 - "Aliskiren reduces morning blood pressure in hypertensive patients with diabetic nephropathy."
09/01/2011 - "• Early evidence suggests that aliskiren confers additional benefit in patients with diabetic nephropathy. "
07/01/2010 - "However, the detailed effect of aliskiren on type 2 diabetic nephropathy is still unknown. "
10/01/2009 - "Aliskiren, added to standard therapy, shows additional and significant antiproteinuric effects in patients with diabetic nephropathy. "
03/01/2013 - "These results suggest that the beneficial organ protective effect of aliskiren is mediated by improvement in insulin resistance as well as a direct anti-fibrotic effect in the target organ in STZ-induced diabetic rats with a slight effect on blood pressure. "
04/01/2011 - "Together, these results imply that aliskiren provides an organ-protective effect through improvement in insulin resistance and lipid abnormality, as well as direct anti-fibrotic effect in target organ in db/db mice. "
03/01/2013 - "Aliskiren improves insulin resistance and ameliorates diabetic renal vascular complications in STZ-induced diabetic rats."
04/01/2011 - "Aliskiren improves insulin resistance and ameliorates diabetic vascular complications in db/db mice."
02/01/2013 - "In conclusion, our findings suggest that aliskiren prevents and ameliorates insulin resistance, aortic endothelial dysfunction and oxidative vascular remodeling in fructose-fed hypertensive rats."
01/01/2013 - "After aliskiren treatment, there was a significant reduction in proteinuria in 4 weeks (1.76±0.95 to 1.03±0.69 g:g-Cr, p<0.0001), which remained at a low level throughout the treatment period. "
05/01/2011 - "The results of the Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Disease Endpoints (ALTITUDE) trial which has already included 8600 patients with type 2 diabetes, proteinuria and a high cardiovascular risk and compared the effects of aliskiren vs. a placebo on a composite endpoint including renal and cardiovascular morbidity and mortality should be provided in 2012."
05/01/2011 - "Our post hoc analysis assessed the baseline BP influence on the antiproteinuric effect in the Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) study. "
02/01/2009 - "An issue of dependence: implications from the Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial."
09/01/2014 - "Adding aliskiren on ACEi or ARB in CKD patients, both in diabetes and non-diabetes, has a favorable effect on reducing residual proteinuria and inadequately controlled blood pressure."
|6.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
|7.||Angiotensin Receptor Antagonists
|9.||Angiotensin Receptors (Angiotensin II Receptor)
|2.||Transplantation (Transplant Recipients)
|5.||Renal Dialysis (Hemodialysis)